Openbookopenbook
Equity
NTLA
+0.0 · +0.00%
USD · NASDAQ

Intellia Therapeutics Inc(NTLA) Stock Analysis | Healthcare

USD --+0.00%
Reward49Moderate
Risk57Medium-High
75%Data
Revenue down 46% YoY
Earnings Deterioration
Market Cap:1.80Bn
ⓘ
Reward Rating
49
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
57
Medium-High
Risk Assessment
5 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on NTLA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for NTLA, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $23.94.

What is Intellia Therapeutics Inc?

operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

NTLA · Verdict

Moderate reward · elevated risk

NTLA's standout is balance sheet; cash flow and volatility weigh on the picture.

Based on 88% data coverage

NTLA · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet86/100

    Current ratio 5.08

Watchouts 3

  • Cash flow20/100

    -524% free-cash-flow margin

  • Volatility20/100

    Weak vs peers

  • Profitability32/100

    -610% net margin · -55% ROE

Model-based scoring. For information only — not financial advice.

What is Intellia Therapeutics Inc?

operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.80B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (49)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

LKFTSmall Cap / 1.8B market cap
Lakefront Biotherapeutics NV
Compare
ONTTFSmall Cap / 1.8B market cap
Oxford Nanopore Technologies Limited
Compare
SNDXSmall Cap / 1.8B market cap
Syndax Pharmaceuticals Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap1.80B
P/E RatioN/A
Dividend YieldN/A
Beta1.794
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
353,051 shares
$489k
0
9-12months
21,902 shares
$33k
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.